[Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].

Abstract

AIM:

To study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH).

MATERIAL AND METHODS:

A total of 60 patients with verified diagnosis of essential AH of the second degree were randomized into two groups: group 1 (n=40) received proxodolol, group 2 (n=20) was given carvedilol. The trial lasted for 89 days.

RESULTS:

The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH.

CONCLUSION:

Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg.

• Authors: S A Beliaeva
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 83 Issue 4 Pg. 52-5 ( 2011) ISSN: 0040-3660 [Print] Russia (Federation)
• PMID: 21675275 (Publication Type: Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic alpha-Antagonists
• Adrenergic beta-Antagonists
• Delayed-Action Preparations
• Oxadiazoles
• proxodolol

Topics

• Administration, Oral
• Adrenergic alpha-Antagonists (administration & dosage, therapeutic use)
• Adrenergic beta-Antagonists (administration & dosage, therapeutic use)
• Blood Pressure (drug effects)
• Delayed-Action Preparations
• Dose-Response Relationship, Drug
• Follow-Up Studies
• Humans
• Hypertension (diagnosis, drug therapy, physiopathology)
• Oxadiazoles (administration & dosage, therapeutic use)
• Russia
• Severity of Illness Index
• Treatment Outcome